LDS/Medical Tests/Complete Autoimmune (Connective Tissue Autoimmune) Disease Panel

Complete Autoimmune (Connective Tissue Autoimmune) Disease Panel

Autoimmune Diseases are diseases that occur when the body’s immune system attacks healthy cells in the body. Although there is evidence of association of chronic infections (viral, bacterial, and fungal) with autoimmune disease, the etiology of autoimmune disease still remains unknown. Simply, autoantibodies (antibodies directed to “self” antigens) to some cell parts are developed causing cell damage, which then becomes a chronic disorder with tissue damage. Diagnosis of autoimmune disease can be difficult since the etiology is often not known and because these diseases have similar symptoms.

Autoimmune disease can be systemic (affecting all organ systems), or localized to one organ or tissue type. Localized disease may remain local or spread to nearby or different tissues, but usually does not become systemic. All autoimmune diseases share similar symptoms such as muscle aches, low-grade fever, tiredness, and fatigue. Autoimmune disease typically is diagnosed when a patient exhibits markers for the disease such as antibody to specific cell markers or proteins. There are more than 80 autoimmune diseases that can target almost any part of the body.

To help diagnose these diseases, a physician may order a Complete Autoimmune Disease Panel. A few examples of autoantibodies are antinuclear antibody, rheumatoid factor, and collagen antibodies. Several factors influence the development of autoantibodies; these include genetics, age, and exogenous (external) factors. It should be noted that exacerbations and remissions often occur; disease is not always progressive, and hormonal influences such as estrogen are believed to play a part in some autoantibody diseases such as SLE (systemic lupus erythematosus). Among autoimmune antibodies causing connective tissue diseases are antinuclear antibodies that often appear in patient serum before any definite symptomatic signs. Testing for these antibodies often allows the identification of the specific connective tissue disease. The quantity of some of these autoantibodies, in particular the anti-dsDNA, provides vital information on progression of the disease and for monitoring treatment. Other known antibodies are Anti-SSA and anti-SSB antibodies; either one or both of these may be observed in connective tissue diseases such as Sjögren’s syndrome and systemic lupus erythematosus.

Other known autoantibodies are anti-RNP antibodies that are found primarily in mixed connective tissue disease. They can be observed in SLE, but in lower titer (quantity). Anti-Sm antibodies are another antibody found in SLE and some other autoimmune diseases. Anti-ribosomal antibodies are strongly associated with central neurological abnormalities in lupus, and Anti-Scl70 antibodies are specific for diffuse scleroderma. Anti-Jo1 antibodies are found exclusively in sera from patients suffering from polymyositis, and anti-centromere antibodies are most often found in sera from patients having the CREST syndrome and less often in scleroderma.

This panel includes ANA Screen with reflex to antigen specific antibody, C3 and C4, Complement components, DNA (ds) Antibody, and Rheumatoid Factor.

  • Diagnosis of Systemic Lupus Erythematosus
  • Diagnosis of Rheumatoid Arthritis
  • Diagnosis of Scleroderma
  • Diagnosis of Polymyositis
  • Diagnosis of Dermatomyositis
  • As an aid in diagnosis of Sjögren syndrome
  • As an aid in diagnosis of scleroderma
  • As an aid in diagnosis of vasculitis
  • As an aid in diagnosis of other autoimmune diseases

Increased in:

  • Systemic Lupus Erythematosus
  • Inflammatory myopathies
  • Sjögren syndrome
  • Scleroderma
  • Rheumatoid Arthritis
  • Vasculitis
  • Paraneoplastic syndrome
  • Endocarditis
  • Fibromyalgia
  • Chronic fatigue syndrome
  • Sarcoidosis
  • Nephrotic syndrome
  • Acute Poststreptococcal Glomerulonephritis
  • Other autoimmune diseases

Negative (No Antobody Detected)
 

 

Enzyme Linked Immunosorbent Assay, Indirect Fluorescent Antibody. 

Serum (SST).

Stability

  • Ambient: 1-3 days
  • Refrigerated: 7 days
  • Frozen: 30 days
Complete Blood Count, ESR, C-Reactive Protein, Extractible Nuclear Antigen Antibodies, Antiphospholipid Antibody, ANA by IFA, ASO Fibrinogen, Complement profile.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Clin Exp Rheumatol. 1997 Jul-Aug;15(4):457-65. [PMID: 9272315]
  • Autoimmun Rev. 2007 Jun;6(6):334-40. [PMID: 17537377]
  • Biomed Pharmacother. 2006 Dec;60(10):648-55. [PMID: 17064873]
  • Clin Rheumatol. 1990 Mar;9(1 Suppl 1):100-10. [PMID: 2203588]
  • Clin Med Res. 2005 Aug;3(3):190-3. [PMID: 16160075]
  • Dermatol Clin. 1994 Jan;12(1):161-73. [PMID: 8143379]
  • Am Fam Physician. 2003 Dec 1;68(11):2179-86. [PMID: 14677663]
  • Mayo Clin Proc. 1995 Feb;70(2):183-4. [PMID: 7845044]
  • Turgeon ML. Immunology and Serology in Laboratory Medicine. The C.V. Mosby Company. St. Louis, Missouri (1990).